Heart Failure

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

Findings showed that pharmacists frequently communicated with patients to implement complex plans.

Initiating and optimizing heart failure guideline-directed medical therapy is critical to the comprehensive management of heart failure.

Cardioprotective antihyperglycemic agents are underutilized for inpatient care in heart failure patients. Lack of use can lead to preventable patient deaths and hospital readmissions.

The investigators identified 4 prognostic factors with high predictive ability and supported by moderate to high strength evidence beyond what is already available for cardiovascular disease.

Leg compression therapy was associated with decreased brain natriuretic peptide levels without any adverse events for patients with stable chronic heart failure.

Investigators determined the effectiveness of behavioral activation psychotherapy versus antidepressant medication management for inpatients with heart failure and depression.

A signaling pathway linking autophagy to nicotinamide adenine dinucleotide (NAD+), found indications that NAD+ depletion can lead to heart muscle cell dysfunction.

High intensity interval training (HIIT) showed improved heart failure outcomes compared to medium chain triacylglycerol, used for endurance performance among athletes, and the usual care.

Conclusions could not be made regarding whether lower risk was associated with improvement in heart failure or if the success of optimal medications led to better clinical outcomes.

In-hospital mortality and the Medicare Bundled Payments for Care Improvement (BPCI) model are not associated with changes in odds for Black individuals or female individuals.

From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.

In a study, most patients had specified SBP targets of less than 160 mmHg and all patients attained goal within a relatively short period of time.

The results of the study show the importance of considering neighborhood-level disparities to address and improve medication adherence, according to investigators.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

In mice with heart failure, radiation therapy demonstrated improved heart function, specifically in the left ventricle, and reduced inflammation in the heart.

Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.

Heart failure is a major cause of morbidity and mortality for adults with congenital heart disease (CHD), with the highest risk being for those with complex CHD lesions.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

Improvements were seen in left ventricular ejection fraction, NYHA Functional Class, and Minnesota Living with Heart Failure Questionnaire at 1-year post-dose.

In human heart tissues, investigators found that the mechanism associated with heart failure can be reversed and Dicer activity can be restored when AD-9308 was used.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

How pharmacy teams can remove cost barriers to cardiac care.

Anemic individuals with heart failure with preserved ejection fraction displayed unique pathophysiological features that led to reduced exercise capacity.

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.